Kenvue

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kenvue (KVUE) reports strong Q2 earnings, eyes China growth

Kenvue's Q2 performance showcased robust net sales, organic growth, and strategic investments in key segments. The company's focus on consumer trust, supply chain enhancements, and capital allocation strategy underpin its resilience. Challenges include managing inflationary pressures and sustaining growth post-COVID, but opportunities in China and ongoing investments position Kenvue for future success.

Kenvue (KVUE) reports solid Q3 performance amidst segment challenges

Kenvue (KVUE) delivered a solid Q3 performance, showcasing strength in key segments despite challenges in others.
The company's strategic initiatives, focus on innovation, and outlook for growth opportunities position it well for future success.
Efforts to address challenges in specific segments and capitalize on opportunities demonstrate a proactive approach to sustaining growth and profitability.
Overall positive outlook on third-quarter results reflects the company's strong model, portfolio, and cash flow generation capabilities.

Kenvue reports mixed 2023 performance, focuses on growth strategies

Kenvue's 2023 performance saw organic growth but faced challenges in specific segments, leading to adjustments for 2024. The company aims to drive growth through operational efficiencies, increased brand investments, and a focus on consumer engagement. Challenges in U.S. in-store execution prompted a recovery plan and leadership changes.

Kenvue surpasses Q1 expectations, eyes China growth amid challenges

Kenvue's Q1 performance exceeded expectations, driven by key segments and brands.
Strategic focus on cost optimization, operational efficiency, and brand impact.
Challenges include stabilizing declining segments and managing hyperinflation impact.
Opportunities lie in growing China business, operational reinvention, and new leadership.

Kenvue reports solid Q2 performance and optimistic outlook for 2024

Kenvue's Q2 performance reflects steady growth and improved profitability, driven by strategic initiatives and strong brand performance. While cost management and increased marketing spend pose challenges, the company's focus on brand investment and long-term value creation offers promising opportunities for future growth and shareholder returns.

Kenvue reports Q3 growth, tackles Skin Health challenges, eyes savings

Kenvue's Q3 performance showed organic growth and strong financial metrics.
While facing challenges in the Skin Health segment, the company is focusing on recovery.
Investments in marketing and efficiency improvements highlight growth opportunities.
Executives addressed key questions on guidance, inventory levels, and growth strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

Johnson & Johnson

J&J's consumer health unit Kenvue aims to raise $3.5 billion or more in the initial public offering, sources told the Wall Street Journal.

Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report says

Johnson & Johnson (NYSE:JNJ) is reportedly discussing the spin-off and initial public offering (IPO) of its consumer business Kenvue with investors, in a move set to test the waters of the subdued market. Kenvue will meet with investors as early as Monday to discuss the float, according to the Wall Street Journal, in a bid to raise over US$3.5bn on the New York Stock Exchange in the coming weeks.

Johnson & Johnson to eye up IPO market with consumer brand spin-off

BKV Corp

Fidelis Insurance Holdings Ltd

Hanryu Holdings Inc

Jayud Global Logistics Ltd

ACELYRIN Inc

Top Kingwin Ltd

Trio Petroleum Corp

Interactive Strength Inc

U Power Ltd

US Goldmining Inc

Wang & Lee Group Inc

U.S. IPO Weekly Recap: IPO Market Has A Full Week Of Small Deals, Led By Chinese Issuers.

U.S. IPO Weekly Recap: IPO Market Has A Full Week Of Small Deals, Led By Chinese Issuers

As Johnson & Johnson readies for the separation of its consumer health division later this year into the consumer-focused company called Kenvue, the healthcare giant's first quarter was marked by continuing moves away from COVID-era focuses and into areas like robotic surgery.

Johnson & Johnson Preps for Kenvue Spinoff While Noting Strong Q1 in OTC

ARB IOT Group Ltd

Atmus Filtration Technologies Inc

Golden Heaven Group Holdings Ltd

Cytomed Therapeutics Ltd

Global Mofy Metaverse Ltd

Ispire Technology Inc

Millennium Group International Holdings Ltd

Multi Ways Holdings Ltd

Simpple Ltd

VCI Global Limited

Four small issuers began trading this past week. Two small IPOs submitted initial filings.

U.S. IPO Weekly Recap: Small Deals Drive Activity In The IPO Market's Short Week

Kenvue Inc., the consumer products spinoff from Johnson & Johnson JNJ, +0.89% , has grown the roster of banks underwriting its initial public offering beyond the two original leads . Goldman Sachs & Co. LLC and JP Morgan, according to a filing on Friday.

J&J Kenvue spinoff adds slew of banks to its initial public offering roster

AbbVie

Amgen

Boeing

General Dynamics

Kimberly-Clark

L3Harris

Lockheed Martin

Altria

Merck

Northrop Grumman

Philip Morris

Raytheon Technologies

Investing in blue-chip companies that pay dividends and relentlessly focusing on reinvesting the proceeds is a proven strategy for reliable long-term returns. But what about the occasional black swan? Potentially devastating litigation? Overlooked liabilities on the balance sheet? Financial engineering?

Blue-Chip Stocks And Red Flags - Things To Consider In Your Due Diligence

As markets open for the new year, a mega breakup that could shake up the consumer healthcare market is coming down the initial public offering (IPO) pipeline.

J&J's Spin-Off Kenvue Lists for IPO in Healthcare Giant Split

Kenvue has filed to go public as part of its separation process from parent firm Johnson & Johnson. The company sells consumer healthcare and wellness products worldwide.

Kenvue Begins IPO Process As It Seeks To Separate From Johnson & Johnson

Johnson & Johnson (NYSE:JNJ)'s consumer health unit Kenvue has filed to be listed as an independent company on the New York Stock Exchange under the ticker symbol "KVUE." Kenvue, which J&J says has components signifying knowledge and sight, is a milestone in the healthcare giant's 135-year history.

Johnson & Johnson's Band-Aid and Tylenol company Kenvue files for IPO, moving closer to spin off

Kenvue Inc. KVUE, , the consumer products unit of Johnson & Johnson JNJ, +1.09% , late Wednesday filed its initial public offering as part of a previously disclosed spinoff plan for the business. Kenvue plans to trade on the New York Stock Exchange under the symbol KVUE with lead underwriters Goldman Sachs Group Inc. and JPMorgan Chase & Co. For the fiscal year ended Jan. 2, Kenvue reported $15.05 billion in net sales, and $2.03 billion in net income.

J&J spinoff Kenvue files initial public offering

Johnson & Johnson's consumer health unit on Wednesday filed with the U.S. securities regulator to be listed as an independent company, bringing the healthcare conglomerate a step closer to completing the biggest shake up in its 135-year history.

J&J's consumer health unit Kenvue files for IPO ahead of spin-off

News for Kenvue Stock (KVUE)